We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 1.10 | 1.40 | 1.25 | 1.25 | 1.25 | 592,472 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.57 | 1.69M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/5/2018 11:00 | I've done a mega-thread on PYC Physiomics CEO Dr Jim Millen's Proactive Investors interview last week I think there was so much great info the video needed breaking down and 'annotating' so those less up to speed with the story can appreciate it. Dr Jim Millen comes across as a good solid 'underpromise,overde | the stigologist | |
05/5/2018 21:51 | Ignore STUG/STUCK!! | smcl | |
05/5/2018 21:50 | STIG= STUG/STUCK with 2.75%. Hence INCESSANT RAMPING. A lot to lose!!!!! | smcl | |
05/5/2018 21:07 | Of course, that's how it works doesn't it. I know you only have a spoon to dig with, but because they are your peers, you're gonna be minted! | davevt | |
04/5/2018 22:00 | Dave just answer the question. I turn over 10k a year but given that Glencore BHP et al turn over billions surely I'll be a billionaire too? | spacedust | |
04/5/2018 13:28 | Space, the spamologist 'owns 2.75 percent of the company'. 2.75 percent of a company that has less revenues than my mates pub, oh and less profit too, and 2.75 percent of shares that are worth less than she paid for them. The gap down the back of my sofa has more profit than Stig, and probably more idea how to compare companies. | davevt | |
04/5/2018 12:22 | Dave Spacedust mining 10k a year BhP 100bn a yr Glencoe 200bn a yr I'm going to be a billion year? My prospects are great. I am the founder but I have no shares My directors sold their holding | spacedust | |
04/5/2018 01:21 | Cetara models all drugs for development and dosage, has over 1200 commercial clients, over 200 medical institutions, fda, Chinese and European approval, medical regulators use their software, owns over 6 other Bio companies, revenues of over 80 million a year, and pyc on the other hand only models dosage for tumors only, not other drugs, has about 5 customers, no patents, no fda, and turns over less than my friends pub. You are a total moron to even compare pyc to any other companies. There is a reason why no one else is... | davevt | |
03/5/2018 23:57 | Great video about PYC Physiomics Physiomics PLC: Personalised medicines will build on momentum from recent pharma deals A serious guy (trained Medical Doctor + MBA + Big Pharma experience + licensing+ VC dealmaking) who recognises potential of the market and talks about it in a non-promotional way but has demonstrated track record of delivering for shareholders and aims to deliver 'more of the same' IF the UK investor market does not recognise the value potential of £4m PYC then I expect their peers will and there will be Corporate/Strategic action here Comparitors B2B In-Silico Clinical Trials / BioSimulation / Modelling and Simulation market Certara $850m Simulations Plus $300m B2C Personalised Medicine market DeepMind $500m+ (acquired by Google) GRAIL inc $1000m+ funding from Big Pharma, Bill Gates, Jeff Bezos | the stigologist | |
03/5/2018 16:47 | STUG/STUCK- look at all his postings. For Gawds sake don’t be fooled by the bullying boasting and clear vested interest. CAUTION - STIG..... | smcl | |
03/5/2018 16:30 | That video showed that they only do dosage modelling for tumors. While all their 'comparitors' do modelling to design drugs, and do dosage for drugs.....LOADS of different drugs, not just only cancer as pyc is. So tell me, if you were a pharma, would you use a company that can only do a tiny bit of one area, or ones that can do everything. And that my friends is why pyc only does a few hundred k a year turnover, and it's comparitors do tens to hundreds of million turnover.. | davevt | |
03/5/2018 16:17 | A lot of great info in there :- Despite having signed 3 big pharmas + 1 biotech Still looking to sign MORE NEW CLIENTS Want to get big clients up to Merck level revenues IF PYC get 6 big clients doing Merck type revenue every year that'd be c.£3m revenue a year. On 'Industry Sales multiples' of c.10x that side of the business would be worth £30m Add on the blue sky (software scaleable/holy grail of AI based personalised medicine) very easy to see this get to £100m market cap within 18-24 months | the stigologist | |
03/5/2018 15:40 | Great video about PYC Physiomics Physiomics PLC: Personalised medicines will build on momentum from recent pharma deals A serious guy (trained Medical Doctor + MBA + Big Pharma experience + licensing+ VC dealmaking) who recognises potential of the market and talks about it in a non-promotional way but has demonstrated track record of delivering for shareholders and aims to deliver 'more of the same' IF the UK investor market does not recognise the value potential of £4m PYC then I expect their peers will and there will be Corporate/Strategic action here Comparitors B2B In-Silico Clinical Trials / BioSimulation / Modelling and Simulation market Certara $850m Simulations Plus $300m B2C Personalised Medicine market DeepMind $500m+ (acquired by Google) GRAIL inc $1000m+ funding from Big Pharma, Bill Gates, Jeff Bezos | the stigologist | |
03/5/2018 14:59 | you need to change your name to the Spamologist... | davevt | |
03/5/2018 14:38 | Jim Millen explains Physiomics approach to personlised medicine. | myamay16 | |
03/5/2018 14:15 | Since October 3rd 2017 Dr Jim Millen has shown he is a top class CEO and he delivers Merck have validated PYC service Domino effect has started with two other major Pharmas and a UK biotech signing up to contracts PYC have emerged as a serious player on the Personalised Medicine scene alongside likes of DeepMind/GRAIL I can see this easily becoming a £100m+ Company Would not rule out £1000m+ | the stigologist | |
03/5/2018 14:08 | On October 2nd 2017 Physiomics told us they expected to complete a deal with a Big Pharma On November 28th 2017 they announced that deal. It was 'old news' but the stock still went up 3100% within 48 hours. What will 'new news' do to this stock ? When we know it's comparitors are valued at 100x ! PYC Worth repeating even their clueless brokers Hybridan have never mentioned likes of Certara, DeepMind, GRAIL inc so it will come as a total surprise to 'the market' | the stigologist | |
03/5/2018 14:03 | Higher highs and onwards inexorably higher | the stigologist | |
03/5/2018 13:38 | STUG/STUCK- still stuck on posting his ramblings. Great to have a few opposite viewpoints. Keep it up Dave PWhite73 et al. | smcl | |
03/5/2018 13:19 | Expect this stock to continue to melt up now the trend has changed Reflects increasing understanding of the story by bulls so they are strong hands and concomitant realisation of the complete incompetence/lies of bears being exposed with their failure to understand the Company,the market and the extraordinary confluence of major growth catalysts here. | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions